Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 3/20 | 0.37 |
| ▸ | METAP1 | P53582 | 3/20 | 0.37 |
| ▸ | CASR | P41180 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734722 | 1.00 | EPHX2 (0.41) | EPHX2NQO2MTNR1ASSTR4METAP2 | |
| SCHEMBL3734727 | 1.00 | EPHX2 (0.41) | EPHX2NQO2MTNR1ASSTR4METAP2 | |
| SCHEMBL13040834 | 0.91 | EPHX2 (0.39) | EPHX2SSTR4METAP2METAP1CASR | |
| SCHEMBL13040832 | 0.88 | EPHX2 (0.39) | EPHX2SSTR4METAP2METAP1 | |
| SCHEMBL13040869 | 0.88 | EPHX2 (0.44) | EPHX2MTNR1ASSTR4CASRLMNA | |
| SCHEMBL13040871 | 0.88 | EPHX2 (0.48) | EPHX2SSTR4METAP2METAP1LMNA | |
| SCHEMBL13040870 | 0.88 | EPHX2 (0.44) | EPHX2MTNR1ASSTR4METAP2METAP1 | |
| SCHEMBL13040874 | 0.87 | EPHX2 (0.45) | EPHX2CASR | |
| SCHEMBL13040831 | 0.86 | EPHX2 (0.38) | EPHX2SSTR4CASR | |
| SCHEMBL13040833 | 0.86 | EPHX2 (0.38) | EPHX2SSTR4CASRLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279936-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-11-04 | — | — | US | claimed |
| US-20100279936-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279936-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | C1R, C3AR1, PTH1R | EPHX2 1436/4885NQO2 2416/4885MTNR1A 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.